Targeting the Electron Transport System for Enhanced Longevity.

Area of Science:

• Gerontology and mitochondrial biology.
• Cellular senescence and inflammation research.
• Pharmacological interventions for aging.

Background:

• Mitochondrial DNA (mtDNA) damage disrupts oxidative phosphorylation (OXPHOS), increasing reactive oxygen species (ROS) and inflammation, leading to cellular senescence and tissue degeneration.
• Rapamycin and metformin are key longevity drugs that modulate cellular metabolism and mitochondrial function.
• Emerging small molecules target mitochondrial components, showing promise similar to existing longevity drugs.

Purpose of the Study:

• To review the mechanisms of action for rapamycin and metformin in promoting longevity.
• To introduce novel small molecules targeting mitochondrial function and their potential benefits.
• To discuss optimal strategies for applying mitochondrial interventions for sustained healthspan.

Main Methods:

• Literature review of existing studies on longevity drugs and mitochondrial interventions.
• Analysis of the molecular pathways affected by rapamycin, metformin, and novel small molecules.
• Synthesis of current knowledge on mitochondrial dysfunction and aging.

Main Results:

• Rapamycin inhibits mTORC1, enhancing mitophagy and mitochondrial biogenesis while reducing inflammation.
• Metformin inhibits Complex I, reducing ROS and activating AMPK for autophagy and mitochondrial turnover.
• New compounds like Elamipretide and Sonlicromanol modulate mitochondrial metabolism, offering potential longevity benefits.

Conclusions:

• Both chronic and intermittent administration of mitochondrial interventions require further investigation.
• A combined strategy of chronic metformin use with targeted mitochondrial therapies during stress may be pragmatic.
• Mitochondrial-targeted therapies hold significant potential for promoting longevity and combating age-related decline.